Amyl Therapeutics

Updated: September 02, 2025
CEO Pierre Vandepapelière
CEO Pierre Vandepapelière
Country: Belgium | Funding: €29.7M (+)

Website: https://www.amyltx.com/

Amyl Therapeutics unique technology offers a curative solution for all forms of amyloid mediated diseases

Competitors
Promote Startup